EGFR T790M/L858R-IN-2

• CAT Number: I041372
• CAS Number: 2955607-40-4
• Molecular Formula: C28H28FN7O
• Molecular Weight: 497.57
• Purity: ≥95%
• Synonyms: N-[3-[[6-fluoro-2-[4-(4-methylpiperazin-1-yl)anilino]quinazolin-4-yl]amino]phenyl]prop-2-enamide
• InChI: InChI=1S/C28H28FN7O/c1-3-26(37)30-21-5-4-6-22(18-21)31-27-24-17-19(29)7-12-25(24)33-28(34-27)32-20-8-10-23(11-9-20)36-15-13-35(2)14-16-36/h3-12,17-18H,1,13-16H2,2H3,(H,30,37)(H2,31,32,33,34)
• InChIKey: KDWNVZXLHSMELQ-UHFFFAOYSA-N
• SMILES: CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C=C(C=C4)F)C(=N3)NC5=CC(=CC=C5)NC(=O)C=C

EGFR T790M/L858R-IN-2（Cat No.:I041372）is a small molecule inhibitor designed to target specific mutations in the epidermal growth factor receptor (EGFR), namely T790M and L858R. These mutations are commonly associated with non-small cell lung cancer (NSCLC) and contribute to resistance to first-generation EGFR inhibitors. EGFR T790M/L858R-IN-2 selectively inhibits the mutated EGFR receptor, potentially overcoming resistance and reducing tumor growth. This compound is being investigated in preclinical and clinical trials as a therapeutic strategy for patients with EGFR-mutant NSCLC, offering hope for more effective treatments in combating drug-resistant cancers.